argenx (ARGX) Research Coverage Started at Stifel Nicolaus
Stifel Nicolaus initiated coverage on shares of argenx (NASDAQ:ARGX) in a report released on Thursday morning, The Fly reports. The firm issued a buy rating and a $139.00 price objective on the stock.
Other research analysts have also recently issued research reports about the stock. Wedbush boosted their price objective on shares of argenx from $93.00 to $114.00 and gave the company an outperform rating in a research report on Monday, June 25th. Piper Jaffray Companies reiterated an overweight rating and set a $130.00 price objective on shares of argenx in a research report on Thursday, June 7th. JMP Securities boosted their price objective on shares of argenx from $93.00 to $130.00 and gave the company a positive rating in a research report on Monday, June 18th. ValuEngine upgraded shares of argenx from a hold rating to a buy rating in a research report on Friday, June 1st. Finally, Nomura began coverage on shares of argenx in a research report on Friday, June 29th. They set a buy rating and a $161.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus target price of $125.14.
ARGX stock opened at $93.78 on Thursday. argenx has a twelve month low of $21.25 and a twelve month high of $103.00. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of -66.99 and a beta of 2.07.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Article: Technical Analysis
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.